Luis Sanchez-Perez

A simple method to cure established tumors by inflammatory killing of normal cells.

Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.

Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy.

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.

Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas.

Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.

Toll-like receptors in tumor immunotherapy.

Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.

Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.

Type 17 CD8+ T cells display enhanced antitumor immunity.

Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Research highlights.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Th17 cells are long lived and retain a stem cell-like molecular signature.

Immunotherapy with tumor vaccines for the treatment of malignant gliomas.

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.

Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.